RT Journal Article
SR Electronic
T1 Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4759
OP 4762
VO 36
IS 9
A1 SOTIRIOS SACHANAS
A1 GERASSIMOS A. PANGALIS
A1 PETROS KAROUZAKIS
A1 EFSTATHIOS KOULIERIS
A1 MARIA MOSCHOGIANNIS
A1 CHRISTINA KALPADAKIS
A1 XANTHI YIAKOUMIS
A1 DIMITRA RONTOGIANNI
YR 2016
UL http://ar.iiarjournals.org/content/36/9/4759.abstract
AB Malakoplakia, a rare granulomatous disease of infectious etiology, is commonly observed in immunocompromised patients. Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulation resulting in significant infection-related morbidity and mortality, and several drugs used in CLL treatment have a severe immunosuppressive effect. Ibrutinib, has become a new standard-of-care in patients with CLL, especially for those harboring unfavorable genetic characteristics such as 17 p deletion, with however, unknown long-term immunological consequences. Here we report a case of a patient with CLL with 17 p deletion diagnosed with malakoplakia of the urinary bladder under ibrutinib therapy who developed severe hypogammaglobulinemia during treatment administration. Presumably, ibrutinib might contribute to the development of malakoplakia on the grounds of induced immunosuppression. This case report highlights the need for regular assessment of immunogammaglobulin adequacy during treatment with ibrutinib, considering that it should be given on a permanent basis.